Siena Expands MetaCore License From GeneGo

GeneGo, Inc. has announced that Siena Biotech has expanded the number of MetaCore licenses obtained from GeneGo.

MetaCore's technology platform's capacity to integrate multiple data types including proteomics and chemogenomics data was valued by Siena Biotech together with the quality of content in neurological diseases.

"We appreciate MetaCore's flexibility and GeneGo's ability to quickly implement customer feedback," said Dr. Georg C. Terstappen, Vice President Discovery Research, of the Italian Company.

"GeneGo and Siena Biotech in their respective fields are leading the way in pathway proteomics: we expect advantages for both companies form this collaboration."

"We are very pleased to expand our relationship with Siena Biotech," said Julie Bryant, Vice President of Business Development at GeneGo.

"We are seeing more of our customers expanding the scope of data types analyzed in MetaCore in their R&D efforts."

"MetaCore is well equipped for this with its capacity to concurrently visualize, score and process gene expression, proteomic, metabolomic and compound data."